Within the U.S. Department of Veterans Affairs (VA), including our facility, we believe that limited prescribing uptake of SGLT2 inhibitors and GLP-1 RAs was due to a lack of prescriber experience with these medication classes, discomfort with adjusting diabetes regimens in patients who are already meeting targets, and, in the past, a belief that their use was not supported internally by VA [5]. The gene discussed is GLP1R; the disease is diabetes mellitus.